245.00
+5.20%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zealand Pharma A/S
Its shares trade on Nasdaq Copenhagen under the ticker ZEAL.CO. It has been listed since 1 November 2010. In the fiscal year to 31 December 2025, it reported revenue of DKK 9.21bn and net income of DKK 6.46bn. At that date it held total assets of DKK 16.46bn and shareholders' equity of DKK 14.83bn.
Zealand Pharma A/S is a biotechnology company that engages in the discovery, design and development of peptide based medicines. The firm's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Nov 2010
- Employees
- 329
- Website
- zealandpharma.com ↗
Leadership
Pay as last reported
- Dr. Alf NicklassonIndependent Chairman of the BoardDKK 2.9m
- Mr. Adam SteensbergPresident, Chief Executive Officer, Member of the Executive ManagementDKK 53.9m
- Dr. Kirsten DrejerIndependent Vice Chairman of the BoardDKK 1.4m
- Ms. Henriette WennickeExecutive Vice President, Chief Financial Officer, Member of the Executive ManagementDKK 19.8m
- Mr. Ivan MoellerExecutive Vice President, Chief Operating Officer
- Ms. Christina BredalChief People Officer, Executive Vice President
- Mr. Eric CoxExecutive Vice President, Chief Commercial Officer
- Mr. Utpal SinghChief Scientific Officer
- Mr. Steven JohnsonChief Development Officer
- Mr. David KendallChief Medical Officer, Head of Research and Development
- Mr. Frederik BeckDirector - Employee RepresentativeDKK 611,000
- Ms. Anneline NansenDirector - Employee RepresentativeDKK 611,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 76
- Social
- 99
- Governance
- 56
- Direct emissions (scope 1)
- 145 t
- Energy emissions (scope 2)
- 17 t
- Value chain emissions (scope 3)
- 266,412 t
- Women in the workforce
- 63.09859%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zealand Pharma A/S has a strong focus on research and development, allowing them to continually innovate and develop new pharmaceutical products.
- The company has a diverse pipeline of potential drugs, providing them with a wide range of opportunities for growth and revenue generation.
Weaknesses
- As a relatively small pharmaceutical company, Zealand Pharma may face financial constraints when it comes to funding research and development or marketing initiatives.
- The company's success is strongly tied to the success of their drug candidates, making them vulnerable to setbacks and failures in clinical trials.
Opportunities
- The increasing prevalence of chronic diseases and the aging population provide opportunities for Zealand Pharma to develop and market drugs targeting these conditions.
- Partnerships with larger pharmaceutical companies could provide Zealand Pharma with access to additional resources, expertise, and distribution networks.
Threats
- Competition from other pharmaceutical companies, including larger and more established players, poses a threat to Zealand Pharma's market share and profitability.
- The regulatory environment for drug approval and pricing can be challenging, potentially delaying market entry or affecting pricing strategies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.